1)Dooley KE, et al:Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 34:1607-1612, 2002
2)Shen GH, et al:Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions. Int J Antimicrob Agents 39:201-205, 2012
3)Polk RE, et al:Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 39:497-503, 2004
4)Lautenbach E, et al:Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 162:2469-2477, 2002
5)Chen TC, et al:Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis;A systematic review and meta-analysis. Int J Infect Dis 15:e211-216, 2011
6)Park IN, et al:Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis 11:319-324, 2007
7)Butler CC, et al:Understanding the culture of prescribing;Qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats. BMJ 317:637-642, 1998